Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa
Graphical abstract
Section snippets
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
The authors thank William R. Ewing, Mimi L. Quan, and Joanne M. Smallheer for critical review of this manuscript; the Department of Discovery Synthesis; Dr. Anuradha Gupta, Dr. Manivel Pitchai, and Sankara Narayanan for the synthesis of intermediates at BMS Biocon Research Center; the Department of Lead Discovery & Optimization; and Mojgan Abousleiman for in vitro work. Some of this research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User
References (29)
- et al.
Am Heart J
(2014) - et al.
Drug Discovery Today
(2014) - et al.
J Med Chem
(2014)et al.Thromb Thrombolysis
(2015)et al.ACS Med Chem Lett
(2015)et al.J Pharmacol Exp Ther
(2017)et al.J Med Chem
(2017) Polar surface area
J Med Chem
(2011)- et al.
Bioorg Med Chem Lett
(2005)et al.Bioorg Med Chem Lett
(2008) - In addition, the –CH(CF3)-NH-CH backbone angle is close to 120o observed with an amide, and the C-CF3 bond is isopolar...
- The absolute stereochemistry was assigned based on an X-ray co-crystal of 10 with FXIa. PDB deposition number for 10 is...
- Van Lierop BJ, Lummiss JAM, Fogg DE. Ring-closing metathesis. In: Grela K, ed. Olefin metathesis: theory and practice....
Lancet
(2018)
Arterioscler Thromb Vasc Biol
N Engl J Med
J Med Chem
Eur J Pharmacol
Thromb Thrombolysis
J Med Chem
Bioorg Med Chem Lett
Cited by (4)
Studies on fragment-based design of allosteric inhibitors of human factor XIa
2020, Bioorganic and Medicinal ChemistryCitation Excerpt :The most often used approach of targeting hFXIa is orthosteric inhibition. This has led to the design/discovery of several heterocyclic agents and natural products as highly promising inhibitors.20–33 Prominent among these are the tetrahydroisoquinoline- (Fig. 1), pyridazine-, pyridazinone-, pyridine-, pyrimidine-and imidazole-based agents that bind in the active site of hFXIa.21,24,25,29
Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives
2023, Journal of Medicinal ChemistryDiscovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
2022, Journal of Medicinal ChemistryDiscovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species
2020, Journal of Medicinal Chemistry